Source: Humanigen, Inc.
Humanigen, Inc., (HGEN) (“Humanigen”),
a clinical stage biopharmaceutical company focused on the development
of next generation CAR-T and other cell therapies, announced today that
it is contemplating conducting a broadly syndicated rights offering
involving issuing a dividend of rights and over-subscription rights to
purchase shares of its capital stock (“Shares”) to its stockholders as
of a future record date pursuant to an offering statement on Form 1-A
(the “Offering Statement”) which would be filed with the Securities and
Exchange Commission (the “SEC”).
A broadly syndicated rights
offering is a democratization of the public offering process allowing
all stockholders of record to participate in the process. In this
scenario, stockholders as of the record date would receive a right but
not the obligation to purchase Shares during a to-be-determined exercise
period. Stockholders as of the record date would also receive
over-subscription rights to purchase additional shares beyond their pro
rata percentage ownership. Humanigen has engaged RHK Capital to gauge
feedback and interest for this potential rights offering.
"We
are evaluating conducting a rights offering primarily to raise
additional capital to pursue our GM-CSF neutralization strategy in a
clinical collaboration with Kite, a Gilead company. If we proceed with
this offering to our stockholders, our stockholders will have the first
opportunity to purchase additional securities to maintain or increase
their current percentage ownership in our company and provide capital to
us at what we believe are attractive price levels," stated Cameron
Durant, Humanigen’s chief executive officer.
Please send all
inquiries to croberts@rhk.capital if you are interested in speaking with
an advisor in regards to the Shares and the potential terms for the
rights offering. The company welcomes your feedback as it tests the
waters for this potential rights offering to its stockholders.
About Humanigen
Humanigen, Inc. is developing its portfolio of next-generation cell and
gene therapies for the treatment of cancers via its novel, cutting-edge
GM-CSF neutralization and gene-knockout platforms. There is a direct
correlation between the efficacy of CAR-T therapy and the incidence of
life-threatening toxicities (referred to as the efficacy/toxicity
linkage). We believe that our GM-CSF neutralization and gene-editing
platform technologies have the potential to reduce the inflammatory
cascade associated with serious and potentially life-threatening CAR-T
therapy-related side effects while preserving and potentially improving
the efficacy of the CAR-T therapy itself, thereby breaking the
efficacy/toxicity linkage. The company’s immediate focus is combining
FDA-approved and development stage CAR-T therapies with lenzilumab, the
company’s proprietary Humaneered® anti-human-GM-CSF
immunotherapy, which is its lead product candidate. A clinical
collaboration with Kite, a Gilead Company, was recently announced to
evaluate the sequential use of lenzilumab with Yescarta®,
axicabtagene ciloleucel, in a multicenter clinical trial in adults with
relapsed or refractory large B-cell lymphoma. The company is also
focused on creating next-generation combinatory gene-edited CAR-T
therapies using strategies to improve efficacy while employing GM-CSF
gene knockout technologies to control toxicity. In addition, the company
is developing its own portfolio of proprietary first-in-class
EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various
eosinophilic disorders. The company is also exploring the effectiveness
of its GM-CSF neutralization technologies (either through the use of
lenzilumab as a neutralizing antibody or through GM-CSF gene knockout)
in combination with other CAR-T, bispecific or natural killer (NK) T
cell engaging immunotherapy treatments to break the efficacy/toxicity
linkage, including to prevent and/or treat graft-versus-host disease
(GvHD) in patients undergoing allogeneic hematopoietic stem cell
transplantation (HSCT). The company has established several
partnerships with leading institutions to advance its innovative cell
and gene therapy pipeline. For more information, visit www.humanigen.com
About RHK Capital
Advisory
Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK
Capital is a boutique investment banking firm specializing in small to
medium-sized transactions. RHK is led by a management team with
extensive financial industry experience and a desire to provide
companies and individuals with the tools and expertise to accomplish
their financial goals. In addition to investment banking, RHK has grown
to include businesses in general securities, emerging market securities,
distressed and high yield debt securities, investment management,
mortgages, and business lending. As a division of Advisory Group Equity
Services (AGES), all securities are offered through Advisory Group
Equity Services Ltd., a registered broker-dealer, member of the
Financial Industry Regulatory Authority and the Securities Investor
Protection Corporation.
No comments:
Post a Comment